Evaluating genomic tests for breast cancer management

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, explains the evidence requirements for the clinical development of prognostic and predictive genomic tests for individual risk stratification and adjuvant treatment selection in breast cancer patients.

This content is supported by Genomic Health, Inc.

Year of Production:
Running Time:
Color/Sound:

2016
04:08
Color/Sound

Comments are closed.